We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




Sepsis Host-Response PCR Test Enables Early Targeted Therapies

By HospiMedica International staff writers
Posted on 29 Mar 2023
Print article
Image: The AcuSept PCR Test is a sepsis host-response blood test based on specific biomarkers (Photo courtesy of Pexels)
Image: The AcuSept PCR Test is a sepsis host-response blood test based on specific biomarkers (Photo courtesy of Pexels)

Sepsis is a leading cause of hospital deaths, resulting in significant human and economic costs. The lack of effective antimicrobials to treat sepsis leads to the death of 11 million people annually. Delayed diagnosis of sepsis can increase the risk of developing septic shock by 4-9% per hour. Early identification of sepsis in patients with ambiguous symptoms can help healthcare professionals provide timely targeted treatment, even before the results of confirmatory tests such as microbiology cultures are available. Now, a host (patient) immune response test can identify 19 mRNA biomarkers of infection, sepsis and septic shock, and can also be used to monitor patient response to treatment.

AcuSept from Acumen Diagnostics Pte. Ltd. (Singapore) is a sepsis host-response blood test based on specific biomarkers that evaluates the host's immune response dysregulation during systemic infection and sepsis by analyzing the gene expression signature of 19 leukocyte mRNA biomarkers, using RT-PCR. The sepsis PCR-based diagnostic test generates results within five hours of patient sample collection.

AcuSept results provide valuable information about infection and sepsis risk and progression. The test can diagnose culture-negative sepsis, which can be difficult to detect using traditional microbiology culture tests that are slower and less sensitive. By overcoming these limitations, AcuSept enables patient triage and monitoring and can be used as a complementary tool to clinical assessments and other diagnostic parameters. AcuSept can inform the selection of appropriate treatment bundles based on the severity risk of sepsis, from early sepsis to severe sepsis and septic shock, and allows for the monitoring of patient response to treatment.

Acumen's clinical studies have demonstrated that AcuSept outperforms other single-biomarker tests in detecting sepsis, and is highly effective in diagnosing culture-negative sepsis. The test's superior positive and negative predictive values enable it to detect infection in patients, providing supplementary information to pathogen identification tests. With AcuSept test results, doctors can gain crucial insights into a patient's condition, allowing for more comprehensive assessments and targeted treatment decisions with greater speed.

Related Links:
Acumen Diagnostics 

Gold Member
12-Channel ECG
CM1200B
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Suction Electrode System
Strässle
New
Patient Monitor
Vista 300

Print article

Channels

Critical Care

view channel
Image: Mesenchymal stromal cells are delivered directly into the lungs using a bronchoscope (Photo courtesy of Stem Cell Res Ther. 2025. DOI: 10.1186/s13287-025-04289-3)

Novel Intrabronchial Method Delivers Cell Therapies in Critically Ill Patients on External Lung Support

Until now, administering cell therapies to patients on extracorporeal membrane oxygenation (ECMO)—a life-support system typically used for severe lung failure—has been nearly impossible.... Read more

Surgical Techniques

view channel
Image: Intravascular imaging can improve outcomes for complex stenting procedures in patients with high-risk calcified coronary artery disease (Photo courtesy of Shutterstock)

Intravascular Imaging for Guiding Stent Implantation Ensures Safer Stenting Procedures

Patients diagnosed with coronary artery disease, which is caused by plaque accumulation within the arteries leading to chest pain, shortness of breath, and potential heart attacks, frequently undergo percutaneous... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.